

Surgery versus no surgery of residual disease in patients with metastatic gastro-intestinal stromal tumour

Submission date 29/04/2010	Recruitment status Stopped	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 29/04/2010	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 04/08/2017	Condition category Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

<http://www.cancerhelp.org.uk/trials/a-trial-surgery-imatinib-gastrointestinal-stromal-tumours>

Contact information

Type(s)

Scientific

Contact name

Ms Holly White

Contact details

550 Wilmslow Road
Manchester
United Kingdom
M20 4BX

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00956072

Clinical Trials Information System (CTIS)

2007-002257-23

Protocol serial number

7150

Study information

Scientific Title

A phase III randomised study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate

Acronym

EORTC 62063

Study objectives

The two principle objectives for this study are as follows:

1. To evaluate if surgery of residual disease in patients with advanced gastro-intestinal stromal tumour (GIST) responding to imatinib improves the progression free survival
2. To correlate the pharmacokinetics of imatinib and its metabolites in both arms with the pharmacokinetics of imatinib and its metabolites before randomisation

Ethics approval required

Old ethics approval format

Ethics approval(s)

Central Manchester REC on 04/082009 (ref: 09/H1008/90)

Study design

Randomised interventional treatment trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Sarcoma; Disease: Soft Tissue

Interventions

Eligible patients will be randomised after 6 to 12 months from starting imatinib for metastatic disease, to surgery of residual disease (investigational arm) or not. Patients allocated to the investigational arm will be operated within the 12th month from imatinib onset. Post-operative imatinib treatment will be restored as soon as possible after surgery. Patients allocated to the standard arm will continue imatinib treatment according to standard practice. In both arms, patients will be followed for disease progression and/or discontinuation of imatinib therapy whenever that may be. Thereafter, patients will be followed for survival.

Intervention Type

Mixed

Primary outcome(s)

Progression free survival (PFS), measured from the date of randomisation for surgery

Key secondary outcome(s)

Overall survival (OS) from the time of randomisation to death

Completion date

01/05/2015

Reason abandoned (if study stopped)

Participant recruitment issue

Eligibility

Key inclusion criteria

1. Histologically confirmed GIST expressing CD117+, or with documented mutation of the KIT or PDGFRA gene
2. Metastatic disease (liver and/or abdominal cavity); no extra-abdominal metastases
3. Treatment with imatinib administered for 6 - 12 months, resulting in complete remission (CR), partial remission (PR) or stable disease (SD), without progressive disease (PD) since the start of imatinib therapy (Response Evaluation Criteria in Solid Tumours [RECIST])
4. Measurable disease (RECIST) before start of imatinib
5. Surgically resectable residual disease (assessed on computed tomography [CT] scan/magnetic resonance imaging [MRI])
6. Aged greater than or equal to 18 years (either sex)
7. World Health Organization (WHO) performance status 0 to 1
8. Adequate haematological and organ function

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

No prior treatment with imatinib or other tyrosine kinase inhibitors (for any reason) in the adjuvant or neoadjuvant setting

Date of first enrolment

28/10/2009

Date of final enrolment

01/05/2015

Locations

Countries of recruitment

United Kingdom

England

Australia

France

Germany

Italy

Netherlands

New Zealand

Spain

Study participating centre

550 Wilmslow Road

Manchester

United Kingdom

M20 4BX

Sponsor information

Organisation

European Organisation for Research and Treatment of Cancer (EORTC) (Belgium)

ROR

<https://ror.org/034wxcc35>

Funder(s)

Funder type

Research organisation

Funder Name

European Organisation for Research and Treatment of Cancer

Alternative Name(s)

EORTC

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

Belgium

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No